Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium
Clin Pharmacol Ther. 2012 91 (4): 734-8

PMID: 22378157 · PMCID: PMC3374459 · DOI:10.1038/clpt.2011.355

Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.

MeSH Terms (7)

Animals Dideoxynucleosides Genotype HLA-B Antigens Humans Pharmacogenetics Reverse Transcriptase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities:

Links